Crossmark

Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study

Crossref DOI link: https://doi.org/10.1007/s00277-021-04508-w

Published Online: 2021-04-10

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qu, Wei-ying

Zhao, Lin https://orcid.org/0000-0003-0073-2204
Tan, Xv-cheng

Zhao, Yi-han
License Information

Text and Data Mining valid from 2021-04-10

Version of Record valid from 2021-04-10
More Information

Article History

Received: 7 October 2020

Accepted: 3 April 2021

First Online: 10 April 2021

Declarations

:

: The protocol of the study was approved by the IRB of Shuguang Hospital affiliated with Shanghai University of TCM.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below